ATE482234T1 - Antikörper gegen kdr, deren herstellung und verwendungen - Google Patents

Antikörper gegen kdr, deren herstellung und verwendungen

Info

Publication number
ATE482234T1
ATE482234T1 AT02800666T AT02800666T ATE482234T1 AT E482234 T1 ATE482234 T1 AT E482234T1 AT 02800666 T AT02800666 T AT 02800666T AT 02800666 T AT02800666 T AT 02800666T AT E482234 T1 ATE482234 T1 AT E482234T1
Authority
AT
Austria
Prior art keywords
kdr
disclosed
cdr
antibody
antibody molecules
Prior art date
Application number
AT02800666T
Other languages
English (en)
Inventor
Andrew George Popplewell
Simon Peter Tickle
Karen Zinkewich-Peotti
Robert Kendall Morrison
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE482234T1 publication Critical patent/ATE482234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fats And Perfumes (AREA)
AT02800666T 2001-10-10 2002-10-10 Antikörper gegen kdr, deren herstellung und verwendungen ATE482234T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124317.9A GB0124317D0 (en) 2001-10-10 2001-10-10 Biological products
PCT/GB2002/004619 WO2003031475A2 (en) 2001-10-10 2002-10-10 Antibodies against kdr, their production and uses

Publications (1)

Publication Number Publication Date
ATE482234T1 true ATE482234T1 (de) 2010-10-15

Family

ID=9923562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800666T ATE482234T1 (de) 2001-10-10 2002-10-10 Antikörper gegen kdr, deren herstellung und verwendungen

Country Status (24)

Country Link
US (2) US7452976B2 (de)
EP (1) EP1438340B1 (de)
JP (2) JP4323312B2 (de)
KR (2) KR20070116110A (de)
CN (1) CN1568331A (de)
AT (1) ATE482234T1 (de)
AU (1) AU2002334135B8 (de)
BR (1) BR0212756A (de)
CA (1) CA2458464A1 (de)
CO (1) CO5580838A2 (de)
DE (1) DE60237778D1 (de)
DK (1) DK1438340T3 (de)
EA (1) EA010970B1 (de)
ES (1) ES2351208T3 (de)
GB (1) GB0124317D0 (de)
HU (1) HUP0401618A3 (de)
IL (1) IL160849A0 (de)
IS (1) IS7173A (de)
MX (1) MXPA04003274A (de)
NO (1) NO20040987L (de)
NZ (1) NZ532758A (de)
PL (1) PL208848B1 (de)
WO (1) WO2003031475A2 (de)
ZA (1) ZA200401910B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2377252C2 (ru) * 2003-07-22 2009-12-27 Шеринг Акциенгезельшафт Rg1 антитела и их применение
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2368995A3 (de) * 2005-03-25 2012-01-18 National Research Council of Canada Verfahren zur Isolierung von löslichen Polypeptiden
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CA2631195C (en) * 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
EP2046833B9 (de) 2006-07-14 2014-02-19 AC Immune S.A. Humanisierter antikörper gegen amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
HUE042114T2 (hu) * 2009-02-17 2019-06-28 Ucb Biopharma Sprl Humán OX40-re specifikus ellenanyag-molekulák
CN101531718B (zh) * 2009-04-22 2011-11-02 中国人民解放军南京军区军事医学研究所 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
US9109216B2 (en) 2009-09-24 2015-08-18 Ucb Pharma, S.A. Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
LT2731973T (lt) 2011-07-13 2018-02-26 Ucb Biopharma Sprl Bakterijų padermė, ekspresuojanti rekombinantinį dsbc
KR102027603B1 (ko) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 항-kdr 항체 및 사용 방법
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
JP6067754B2 (ja) 2012-02-24 2017-01-25 アルテオジェン インコーポレイテッドＡｌｔｅｏｇｅｎ Ｉｎｃ． システイン残基を含むモチーフが結合した修飾抗体、前記修飾抗体を含む修飾抗体−薬物複合体及びその製造方法
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US9963512B2 (en) 2012-11-21 2018-05-08 Pharmabcine Inc. Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies
CA3113223A1 (en) * 2018-09-19 2020-03-26 Totient, Inc. Cancer associated antibody compositions and methods of use
WO2020132654A1 (en) * 2018-12-20 2020-06-25 Albert Einstein College Of Medicine Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6204011B1 (en) 1997-06-18 2001-03-20 Merck & Co., Inc. Human receptor tyrosine kinase, KDR
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2000044777A1 (en) * 1999-01-29 2000-08-03 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof

Also Published As

Publication number Publication date
CA2458464A1 (en) 2003-04-17
ES2351208T3 (es) 2011-02-01
WO2003031475A3 (en) 2004-03-25
IL160849A0 (en) 2004-08-31
JP2009108086A (ja) 2009-05-21
JP2005516590A (ja) 2005-06-09
US20090269840A1 (en) 2009-10-29
KR20040097983A (ko) 2004-11-18
AU2002334135B8 (en) 2009-01-29
EP1438340A2 (de) 2004-07-21
BR0212756A (pt) 2004-11-16
US20050181448A1 (en) 2005-08-18
NO20040987L (no) 2004-05-10
WO2003031475A2 (en) 2003-04-17
NZ532758A (en) 2008-04-30
PL370344A1 (en) 2005-05-16
PL208848B1 (pl) 2011-06-30
IS7173A (is) 2004-03-05
CN1568331A (zh) 2005-01-19
HUP0401618A2 (hu) 2004-11-29
DE60237778D1 (de) 2010-11-04
JP4323312B2 (ja) 2009-09-02
KR20070116110A (ko) 2007-12-06
US7842787B2 (en) 2010-11-30
MXPA04003274A (es) 2004-07-08
EA200400519A1 (ru) 2004-12-30
GB0124317D0 (en) 2001-11-28
EP1438340B1 (de) 2010-09-22
ZA200401910B (en) 2005-03-09
HUP0401618A3 (en) 2012-03-28
AU2002334135B2 (en) 2009-01-08
CO5580838A2 (es) 2005-11-30
DK1438340T3 (da) 2010-11-22
US7452976B2 (en) 2008-11-18
WO2003031475A8 (en) 2004-10-14
KR101018908B1 (ko) 2011-03-02
EA010970B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
LTPA2017043I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
CY1121173T1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties